Champions Oncology, Inc. (CSBR) |
| 4.87 0.03 (0.62%) 10-12 13:46 |
| Open: | 4.94 |
| High: | 4.94 |
| Low: | 4.8 |
| Volume: | 6,850 |
| Market Cap: | 68(M) |
| PE Ratio: | -30.44 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 5.64 |
| Resistance 1: | 5.24 |
| Pivot price: | 4.95 |
| Support 1: | 4.59 |
| Support 2: | 3.82 |
| 52w High: | 8.31 |
| 52w Low: | 4.59 |
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
| EPS | -0.070 |
| Book Value | 0.280 |
| PEG Ratio | 0.00 |
| Gross Profit | 2.171 |
| Profit Margin (%) | -1.87 |
| Operating Margin (%) | -2.69 |
| Return on Assets (ttm) | -1.8 |
| Return on Equity (ttm) | -28.4 |
Thu, 08 Oct 2026
Champions Oncology Q4 2026 Earnings Call Transcript - Benzinga
Thu, 08 Oct 2026
Champions Oncology Q3 2026 Earnings Call Transcript - Benzinga
Thu, 08 Oct 2026
Full Transcript: Champions Oncology Q1 2027 Earnings Call - Benzinga
Tue, 15 Sep 2026
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth - The Globe and Mail
Mon, 14 Sep 2026
Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ... - Yahoo Finance
Thu, 10 Sep 2026
CHAMPIONS ONCOLOGY ($CSBR) Releases Q1 2027 Earnings - Quiver Quantitative
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |